FujiFilm Diosynth plans to produce Regeneron's biologic medicines over 10 years in its Holly Springs facility, which is ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

On Tuesday, Fujifilm Diosynth announced a 10-year agreement worth more than $3 billion to make medicines for the New York drugmaker Regeneron in the Triangle. Regeneron is the facility’s third major ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

Regeneron employee works on a pharmaceutical drug. Photo courtesy of Regeneron Pharmaceuticals HOLLY SPRINGS, N.C. – FujiFilm Diosynth Biotechnologies today announced ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

Regeneron is the facility’s third major ... invest $2 billion and bring 725 jobs to a new manufacturing site in Holly Springs, a Wake County town of 46,000 southwest of Raleigh.